194669-41-5

Basic information

• Product Name: 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-(2-methoxyphenyl)-, 1,1-dimethylethyl ester
• CAS NO: 194669-41-5
• Molecular Formula: C17H23NO3
• Molecular Weight: 289.375
• Mol File: 194669-41-5.mol

Chemical Properties

• CAS DataBase Reference: 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-(2-methoxyphenyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-(2-methoxyphenyl)-, 1,1-dimethylethyl ester(194669-41-5)
• EPA Substance Registry System: 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-(2-methoxyphenyl)-, 1,1-dimethylethyl ester(194669-41-5)

Safety Data

• Hazardous Substances Data: 194669-41-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-(2-methoxyphenyl)-, 1,1-dimethylethyl ester is used as a broad-spectrum antibiotic for treating various bacterial infections. It is particularly effective against respiratory tract infections, skin and soft tissue infections, and sexually transmitted diseases. Roxithromycin is valued for its relatively low risk of side effects and its ability to target a wide range of bacterial pathogens.
Used in Research and Development:
In the field of medical research, 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-(2-methoxyphenyl)-, 1,1-dimethylethyl ester serves as a valuable compound for studying the mechanisms of antibiotic action and resistance. It can be used to develop new drugs or improve existing ones, potentially leading to more effective treatments for bacterial infections.
Used in Drug Delivery Systems:
Similar to gallotannin, roxithromycin can also be incorporated into novel drug delivery systems to enhance its efficacy and bioavailability. These systems may include organic and metallic nanoparticles, which can improve the delivery of the antibiotic to target sites, reducing the required dosage and minimizing potential side effects.

Upstream product

• 201609-28-1 1-t-Butoxycarbonyl-4-hydroxy-4-(2-methoxyphenyl)piperidine 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 5720-06-9 2-Methoxyphenylboronic acid 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 578-57-4 2-bromoanisole 

Downstream Products

• 201609-29-2 1-t-Butoxycarbonyl-4-(2-methoxyphenyl)piperidine 
• 154422-95-4 1,2,3,6-tetrahydro-4-(2-methoxyphenyl)pyridine 
• 1276045-14-7 cyclopropyl-[4-(2-methoxy-phenyl)-piperidin-1-yl]-methanone 
• 252919-66-7 4-(2-methoxy-phenyl)-piperidine trifluoroacetate 
• 1616294-18-8 2-cyclopropyl-6,7-dimethoxy-4-[4-(2-methoxy-phenyl)-piperidin-1-yl]-quinazoline 
• 58333-75-8 4-(2-methoxyphenyl)piperidine 
• 1376334-48-3 8-chloro-3-(cyclopropylmethyl)-7-[4-(2-methoxyphenyl)-1-piperidinyl]-1,2,4-triazolo[4,3-a]pyridine 

Relevant articles and documents

20-HETE FORMATION INHIBITORS

This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.

Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators

Neurotensin receptor 1 (NTR1) is a G protein coupled receptor that is widely expressed throughout the central nervous system where it acts as a neuromodulator. Neurotensin receptors have been implicated in a wide variety of CNS disorders, but despite extensive efforts to develop small molecule ligands there are few reports of such compounds. Herein we describe the optimization of a quinazoline based lead to give 18 (SBI-553), a potent and brain penetrant NTR1 allosteric modulator.

AROMATIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS

Provided herein are novel aromatic heterocyclic compounds or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and their uses for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and methods for using such compounds or pharmaceutical compositions thereof to treat Alzheimer's disease.

SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1

Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl- cyclopropane carboxamide derivatives as novel melatonin receptor ligands

Two series of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carboxamide derivatives exhibiting diverse functionality at rat MT1 and MT2 receptors are reported. Compounds 11f and 18b (MT 1/MT2 agonist) have human microsomal intrinsic clearance comparable to ramelteon.

Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists

Aryl-tetrahydropyridine derivatives were prepared and their PPARα/γ dual agonistic activities were evaluated. Among them, compound (S)-5b was identified as a potent PPARα/γ dual agonist with an EC50 of 1.73 and 0.64 μM in hPPARα and γ, respectively. In diabetic (db/db) mice, compound (S)-5b showed good glucose lowering efficacy and favorable pharmacokinetic properties.

Tetrahydrobenzindole compounds

A compound of formula (I) for use in the treatment or prevention of mental diseases A is N, CH, C having a double bond or CR5; each of B and Z is independently N, CH or CR1, with the proviso that A is N when B and/or Z is N; R1, R2, R3, R4and R5and n are as defined in the specification.